LTRN

Lantern Pharma Inc

NASDAQ: LTRN · HEALTHCARE · BIOTECHNOLOGY

$3.13

-9.09% today

Updated 2026-06-03

Market cap

$45.80M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.45

Dividend yield

—

52W range

$1 – $6

Volume

0.8M

Market cap

$45.80M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.45

Dividend yield

—

52W range

$1 – $6

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-10.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$20.00

+538.98%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -10.27 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-3.77M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-14.26M	$-15.96M	$-20.78M	$-17.12M	$-3.33M
EPS	—	—	—	—	$-1.45
Free cash flow	$-12.80M	$-14.37M	$-17.83M	$-15.68M	$-3.77M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LTRN	$45.80M	16	4.3	3.0	5.0	5.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Lantern Pharma Inc trades at $3.13. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -10.27, it sits in the distress.

Frequently asked questions

What is Lantern Pharma Inc's stock price?

Lantern Pharma Inc (LTRN) trades at $3.13.

Is Lantern Pharma Inc overvalued?

Lantern Pharma Inc carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Lantern Pharma Inc (LTRN)?

The 12-month analyst consensus target is $20.00, about 539.0% above the current $3.13. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Lantern Pharma Inc's Altman Z-Score is -10.27, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-157.40%

Beta2.10

50D MA$2.45

200D MA$3.26

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.8M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

LTRN vs LLY →LTRN vs JNJ →LTRN vs ABBV →Stock screener →